Neu­mora's big neu­ro­science plans head to­ward the Nas­daq in sec­ond PhI­II biotech IPO pitch in 24 hours

The large­ly dor­mant biotech IPO mar­ket start­ed siz­zling Fri­day, with two Phase III drug de­vel­op­ers send­ing in their pitch­es for Nas­daq de­buts this fall.

Af­ter Fri­day’s clos­ing bell, the neu­ro­science biotech Neumo­ra sub­mit­ted its pa­per­work to go pub­lic, a day af­ter Rayze­Bio dis­closed its plans by pen­cil­ing in a $100 mil­lion of­fer­ing. The two would join a lit­tle over a dozen biotechs to hit the Nas­daq this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER